4
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- EGFR+
- Tumour stage
- Metastatic
- Control Arm
- Cisplatin + pemetrexed
- Treatment Setting
- 1st line stage III or IV adenocarcinoma with EGFR mutation (Del19/L858R)
- Trial Name
- LUX - Lung 3
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 6.9 months
- PFS Gain
- 6.7 months
- PFS HR
- 0.47 (0.34-0.65)
- QoL Comment
- Improved
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- QoL adjustment
- 1+
- Final non-curative Score
- 4
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate